公开(公告)号：US20230312584A1

公开(公告)日：2023-10-05

申请号：US18033673

申请日：2021-10-21

申请人： VIGONVITA LIFE SCIENCES CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES

发明人： Jingshan SHEN ,  Yuanchao XIE ,  Leike ZHANG ,  Gengfu XIAO ,  Zhen WANG ,  Hualiang JIANG ,  Huaqiang XU ,  Tianwen HU ,  Guanghui TIAN

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  C07B2200/13

摘要： A salt of nucleoside analog, and crystal form, pharmaceutical composition and use thereof. The salt of nucleoside analog has a structure shown in formula I, wherein X is hydrogen or deuterium; Y is an acid, n is 0.5 to 2, or n is 1. When X is hydrogen or deuterium, Y is hydrogen bromide, and n is 1, the salt of the nucleoside analog exists in the form of a crystal with crystal form I or crystal form A or exists in an amorphous form.

公开(公告)号：US20230219993A1

公开(公告)日：2023-07-13

申请号：US17996430

申请日：2021-04-16

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMIY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

发明人： Yuanchao XIE ,  Gengfu XIAO ,  Yang HE ,  Leike ZHANG ,  Heji Akber AISA ,  Hualiang JIANG ,  Jingshan SHEN

IPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

摘要： The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia
(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

公开(公告)号：US20170158680A1

公开(公告)日：2017-06-08

申请号：US15124264

申请日：2015-03-09

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANDONG CO., LTD.

发明人： Hualiang JIANG ,  Zhen WANG ,  Jianfeng LI ,  Rongxia ZHANG ,  Yang HE ,  Yongjian LIU ,  Minghao BI ,  Zheng LIU ,  Guanghui TIAN ,  Weiming CHEN ,  Feipu YANG ,  Chunhui WU ,  Yu WANG ,  Xiangrui JIANG ,  Jingjing YIN ,  Guan WANG ,  Jingshan SHEN

IPC分类号： C07D409/12 ,  C07D495/04 ,  C07D471/04

CPC分类号： C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00

摘要： The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

公开(公告)号：US20210015824A1

公开(公告)日：2021-01-21

申请号：US16978563

申请日：2019-03-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Hong LIU ,  Jia LI ,  Jiang WANG ,  Yi ZANG ,  Jian LI ,  Jingya LI ,  Dandan SUN ,  Hualiang JIANG ,  Kaixian CHEN

IPC分类号： A61K31/5377 ,  A61K31/519 ,  A61P1/16

摘要： Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.

公开(公告)号：US20190100507A1

公开(公告)日：2019-04-04

申请号：US16085311

申请日：2017-03-16

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Hong LIU ,  Jia LI ,  Jiang WANG ,  Mingbo SU ,  Shuni WANG ,  Yubo ZHOU ,  Wei ZHU ,  Wei XU ,  Chunpu LI ,  Hualiang JIANG ,  Kaixian CHEN

IPC分类号： C07D401/12 ,  C07D401/06 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D409/06 ,  C07D417/12 ,  C07D471/04 ,  C07D205/04 ,  C07D265/30 ,  C07D211/38 ,  C07D211/96 ,  A61P35/00

摘要： Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.

公开(公告)号：US20150210711A1

公开(公告)日：2015-07-30

申请号：US14683726

申请日：2015-04-10

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Hong LIU ,  Xin XIE ,  Xuechu ZHEN ,  Haifeng SUN ,  Jing LI ,  Liyuan ZHU ,  Zeng LI ,  Ying CHEN ,  Hualiang JIANG ,  Kaixian CHEN

IPC分类号： C07D491/153 ,  C07D491/056 ,  C07D217/20 ,  C07D311/20 ,  C07C231/14 ,  C07D455/03 ,  C07C69/736

CPC分类号： C07D491/153 ,  C07C69/736 ,  C07C231/14 ,  C07D217/20 ,  C07D311/20 ,  C07D455/03 ,  C07D491/056 ,  C07D491/147 ,  C07D491/22

摘要： The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.

摘要翻译： 本发明涉及由通式（I）表示的新型六氢二苯并[a，g]喹啉化合物及其衍生物，对映体，非对映异构体，外消旋及其混合物，以及其药学上可接受的盐。 本发明还涉及一种制备该化合物的方法，该化合物对神经系统疾病，特别是与多巴胺受体和5-羟色胺受体相关的疾病具有良好的预防和治疗作用。 生物活性实验表明，该化合物预计将发展成为一种新颖有力的化学实体，用于治疗与多巴胺受体和5-羟色胺受体，特别是精神分裂症，帕金森病，药物成瘾，偏头痛等有关的疾病。

公开(公告)号：US20240262860A1

公开(公告)日：2024-08-08

申请号：US18014932

申请日：2021-07-05

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Hong LIU ,  Jiang WANG ,  Yichu LIU ,  Changyue YU ,  Yibing WANG ,  Hualiang JIANG ,  Kaixian CHEN

IPC分类号： C07J63/00 ,  A61K31/704 ,  A61P3/10 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07J63/008 ,  A61K31/704 ,  A61P3/10 ,  A61P31/14 ,  A61P31/16

摘要： The present invention provides a pentacyclic triterpenoid glycoside compound, and a preparation method therefor and a use thereof. Specifically, the present invention provides a compound as shown in formula I. The definition of each group is described in the description. The compound can be used for preparing a medicament for treating metabolic diseases such as diabetes and viral diseases caused by influenza virus, coronavirus and the like.

公开(公告)号：US20230138310A1

公开(公告)日：2023-05-04

申请号：US17759807

申请日：2020-03-26

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  FRONTIER BIOTECHNOLOGIES INC.

发明人： Hong LIU ,  Jian LI ,  Wenhao DAI ,  Jingjing PENG ,  Xiong XIE ,  Shulei HU ,  Chunpu LI ,  Yechun XU ,  Haitao YANG ,  Leike ZHANG ,  Haixia SU ,  Hualiang JIANG ,  Zhenming JIN ,  Gengfu XIAO ,  Kaixian CHEN

IPC分类号： C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/12 ,  C07D411/12 ,  C07D471/04 ,  C07D207/12 ,  A61P31/14

摘要： Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavirus 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavirus infection 2019.

公开(公告)号：US20160074373A1

公开(公告)日：2016-03-17

申请号：US14762980

申请日：2014-01-23

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  THE UNIVERSTIY OF CHICAGO

发明人： Chuan HE ,  Jing WANG ,  Hualiang JIANG ,  Cheng LUO ,  Hong LIU ,  Junyan LU

IPC分类号： A61K31/4365 ,  A61K31/4355 ,  A61K31/4375 ,  A61K31/444

CPC分类号： A61K31/4365 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4741 ,  A61K31/4743 ,  A61K45/06 ,  C07D491/048 ,  C07D491/147 ,  C07D495/04 ,  C07D495/14 ,  A61K2300/00

摘要： Compositions and methods concern organic molecules that bind to human Atox1 and CCS at the copper trafficking interface of these proteins. This binding suppresses copper trafficking, which leads to inhibition of cancer cell proliferation and tumor growth. In addition to serving as an effective treatment of cancer, these organic molecules inhibit cellular copper uptake and can be used as treatment of disorders of copper metabolism such as Wilson's disease, which is characterized by copper overload, as well as wound healing.

摘要翻译： 组合物和方法涉及在这些蛋白质的铜贩运界面处结合人Atox1和CCS的有机分子。 这种结合抑制铜贩运，这导致癌细胞增殖和肿瘤生长的抑制。 除了作为癌症的有效治疗之外，这些有机分子抑制细胞铜摄取，并且可以用作铜代谢紊乱的治疗，例如以铜超载为特征的威尔逊氏病以及伤口愈合。

公开(公告)号：US20240033244A1

公开(公告)日：2024-02-01

申请号：US18004623

申请日：2021-07-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  HANGZHOU LEADING EDGE PHARMACEUTICAL LTD. ,  SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITED

发明人： Cheng LUO ,  Meng XU ,  Shijie CHEN ,  Yilin LI ,  Yantao CHEN ,  Hualiang JIANG ,  Kaixian CHEN ,  Zhanpeng JIANG

IPC分类号： A61K31/343 ,  A61K35/15 ,  A61K39/395 ,  A61K31/216 ,  A61P35/00

CPC分类号： A61K31/343 ,  A61K35/15 ,  A61K39/3955 ,  A61K31/216 ,  A61P35/00

摘要： A YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) attenuating agent, with a compound, and when bound to YTHDF1, the compound binds to amino acid residues 372-392, 479-494 and 526-535 of SEQ ID NO: 1. A modified antigen presenting cell (mAPC), with the mAPC being treated with a YTHDF1 attenuating agent. A composition, with a YTHDF1 attenuating agent, a mAPC treated with the YTHDF1 attenuating agent, and optionally a pharmaceutically acceptable carrier. A method for attenuating an activity of YTHDF1, by administering an effective amount of a YTHDF1 attenuating agent. A method for determining whether or not a candidate agent is a YTHDF1 attenuating agent, by contacting the candidate agent with a YTHDF1 mutant. A method for treating a disease, disorder or condition associated with an expression of an antigen in a subject in need thereof.